Gilead Sciences, Inc.
Market Cap
$179.90B
P/E Ratio
17.78
EPS
$8.15
Dividend Yield
2.20%
52-Week Range
$93.37 — $157.29
Volume
1.74M
Avg Volume
7.27M
Beta
0.37
P/E (TTM)
17.78
Forward P/E
16.67
PEG Ratio
4.15
P/S (TTM)
6.07
P/B (TTM)
7.91
P/FCF
34.83
EV/EBITDA
33.95x
EV/Sales
—
ROE (TTM)
0.41%
ROA (TTM)
0.14%
ROIC
0.07%
Gross Margin
0.81%
Operating Margin
0.37%
Net Margin
0.39%
Debt/Equity
1.09
Current Ratio
1.68
EPS Growth (YoY)
+1.44%
Revenue Growth (YoY)
+0.03%
EPS Growth (3Y)
+5.44%
EPS Growth (5Y)
+13.15%
Sales Growth (3Y)
+0.03%
Sales Growth (5Y)
+0.04%
EPS Est (This Year)
$8.69
EPS Est (Next Year)
$9.63
Dividend Yield
—
Annual Dividend
$0.79
Payout Ratio
0.33%
Frequency
—
Ex-Dividend Date
2025-12-15
Cash/Share
$8.54
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $157.38(8.6% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
1.24B
Float
1.24B
Free Float %
99.77%
RSI (14)
83.30
SMA 20
$138.98
SMA 50
$129.00
SMA 200
$119.39
ATR (14)
4.27
Volatility (Week)
0.03%
Volatility (Month)
0.02%
Pattern
—
1 Day
+5.82%
1 Week
+6.54%
1 Month
+27.08%
3 Months
+31.87%
6 Months
+29.81%
1 Year
—
YTD
+28.13%
All-Time High
$157.29
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
NASDAQ
IPO Date
1992-01-22
Employees
17600
CEO
Daniel O'Day
Index Membership
S&P 500
Website
https://www.gilead.com
Gilead Sciences, Inc. (GILD) is a healthcare company in the drug manufacturers - general industry listed on the NASDAQ. With a market capitalization of $179.90B, a P/E ratio of 17.78, and a dividend yield of 2.20%, GILD is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare GILD against other stocks using dozens of fundamental and technical filters.
Gilead Sciences, Inc. (GILD) has a trailing twelve-month (TTM) P/E ratio of 17.78. This is near the market average range. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Gilead Sciences, Inc. (GILD) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Gilead Sciences, Inc. (GILD) has a market capitalization of $179.90 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Gilead Sciences, Inc. (GILD) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $157.38 implies 8.6% upside from the current price.
Gilead Sciences, Inc. (GILD) has returned +28.13% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.